Acorda Acquires Civitas Together With The Rights To A Promising Antiparkinsonian Agent
American biopharmaceutical company Acorda Therapeutics announced its intention to acquire the company Civitas Therapeutics for $ 525 million dollars. Through the deal Acorda Therapeutics acquired the rights to the experimental drug against Parkinson's disease, which is at the final stage of clinical trials.
We are talking about the drug CVT- 301, which is an inhalation drug based on levodopa, designed to reduce the OFF- periods. CVT- 301 provides rapid delivery of the active substance in the brain of the patient and may be used in conjunction with oral drug therapy of Parkinson's disease.
It is planned that the final clinical trials will start at the beginning of 2015. Join the drug is expected to be registered by the end of 2015. According to the company, on the basis of past trials, CVT- 301 has proven itself as an effective and safe agent for the relief of symptoms of Parkinson's disease.
- Bracelet can treat Parkinsonism
- Anti-Inflammatory Drugs Can Treat Mental Problems
- A new drug for melanoma treatment is registered in the U.S.